|
Omalizumab
resources
|
|
|
|
|
|
DRUG INFO
Omalizumab
Drug Name:
Omalizumab
Indication: For treatment of asthma caused by allergies
Pharmacology: Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.
Mechanism Of Action: Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.
Drug Category: Immunomodulatory Agents; Anti-Asthmatic Agents; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Ig gamma-1 chain C region; Xolair (Genentech Inc)
Dosage Forms: POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Humanized anti-IgE antibody
Chemical Formula: C6450H9916N1714O2023S38 >Anti IgE antibody VL domain chain 1 >Anti IgE antibody VH domain chain 2 >Anti IgE antibody VL domain chain 2
Half Life: 26 days
Drug Type: Approved Drug
# Accession No: BIOD00081
CAS Registry Number: 242138-07-4
|
|
|
|
|
|
Omalizumab News
(When available)
Peanut allergy trial of Xolair halted 16 Jan 2006
United Press International 16 (UPI) -- A clinical trial of the drug Xolair as a way to prevent peanut allergy reactions was halted over safety concerns with an allergy test, a report said ...
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
MSN Money US sales of Xolair(R) (Omalizumab) in 2005 increased 71 percent to $320.6 million from $187.6 million in 2004. Fourth quarter ...
Doctors puzzled by surge in peanut allergies Jan 9, 2006
Maryville Daily Times, The drug Xolair is being examined as a way to quiet the immune system and increase the amount of allergen necessary to set off an anaphylactic reaction. ...
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
Yahoo! News (press release) US sales of Xolair® (Omalizumab) in 2005 increased 71 percent to $320.6 million from $187.6 million in 2004. Fourth quarter ...
PDL Shares Slip on Genentech Results Jan 11, 2006
MSN Money PDL also receives payments on Genentech's Herceptin, a breast cancer therapy, its Xolair asthma drug and the Raptiva psoriasis treatment. ...
Genentech's Shares Fall On Disappointing Avastin Sales Jan 11, 2006
BioWorld Online (subscription), Immunology products Xolair (omalizumab) and Raptiva (efalizumab) had fourth-quarter sales of $93.3 million (compared to $60.3 million) and $20.4 million ...
Tanox to Present at JP Morgan Healthcare Conference Jan 4, 2006
PR Newswire (press release), Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. ...
Genentech's Product Mix Could Boost Margins In 2006 Jan 11, 2006
Forbes Sales of Tarceva, Genentech’s lung and pancreatic cancer drug, and Xolair, for allergic asthma, also beat the analyst’s estimates. ...
Chief is stepping down as Tanox drug steps up Jan 10, 2006
Houston Chronicle, Working with Genentech and Novartis, Tanox developed Xolair, the first biological therapy for allergic asthma, which was approved for sale in Europe in October ...
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
Yahoo! News (press release) Inc. (Herceptin®, Xolair®, Raptiva® and Avastin(TM)); MedImmune, Inc. (Synagis ... Inc. Xolair is a trademark of Novartis AG. Synagis ...
Tanox Submits Investigational New Drug Application for TNX-650 for ... Dec 20, 2005
PR Newswire (press release), Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed allergic asthma. ...
Additional Phase 2 Data Supports Further Development of Tanox's ... Dec 18, 2005
Biotech Intelligence (press release), Tanox's first- approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. ...
Reasonable premium Dec 20, 2005
Reuters ...the third quarter) and Herceptin (up 70% to15.8% of US revenue), along with the introduction late last year of Tarceva, and its asthma treatment Xolair (up 51 ...
Tanox shares rise on clinical study results Dec 19, 2005
Houston Business Journal, 2006. In October, Tanox's asthma drug Xolair received approval in Europe. By Monday afternoon, the company's stock was up 4.3 percent to $16.38. ...
Tanox stock price makes upward turn Dec 26, 2005
Houston Business Journal, ...president and CEO of Tanox. In October, Tanox announced European approval for Xolair, the first commercialized product for the company.
|
|
|
